We verify, using established cut-off values, that high expression of CysLT1 is significantly associated with reduced survival from metastatic disease and reduced overall survival in a second, independent validation cohort of patients with primary UM. The gene discussed is CYSLTR1; the disease is metastatic neoplasm.